Chronic Kidney Disease stage4 Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
The aim of this Phase 2 study is to evaluate the safety and efficacy of the live biotherapeutic product, KT-301 (formerly US-APR2020), in the management of patients with CKD Stage IV.
Kidney diseases are a global public health problem that affects over 200 million people worldwide. It is estimated that about 30 million adults in the United States have Chronic Kidney Disease (CKD) and most are undiagnosed. In addition, CKD represents the ninth leading cause of death in the United States. Kidney diseases also represent great socio-economical cost worldwide. In the United States, treating Medicare beneficiaries with CKD costed over $79 billion, and treating people with End Stage Kidney Disease (ESKD) costed an additional $35 billion in 2016. To date, there is no cure for CKD. The most important CKD risk factors in adults include diabetes and high blood pressure. Other risk factors include heart disease, obesity, a family history of CKD, past damage to the kidneys, and old age. Having CKD increases the chances of also having heart disease and stroke. CKD is a condition characterized by a gradual loss of kidney function over time. Depending on the kidney function measured with glomerular filtration rate (GFR) CKD can be classified into several stages (I, II, III, IV and V). CKD Stage V, also known as End Stage Kidney Disease (ESKD), is a very advanced stage of kidney disease where the kidneys have lost nearly all ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Treatment may slow the decline in kidney function and failure. However, not everyone with CKD develops ESKD, and in some cases ESKD develops even with treatment. CKD is accompanied by altered pathogenic gut bacteria, inflammation, and accumulation of uremic toxins in the blood. These blood uremic toxins can diffuse passively into the bowel. Scientific research has shown that probiotic bacteria could metabolize various uremic toxins such as urea, uric acid, and creatinine. In addition, by supplementing the gut microbiome with probiotic bacteria, it is possible to metabolize the nitrogenous waste products and other toxins which diffuse into the gut, and thus lower levels of inflammation and blood uremic toxins. KT-301 (formerly US-APR2020) is a live biotherapeutic (LBT) intended to restore the gut microbiome to improve the removal of uremic toxins in the bowel in CKD patients. The aim of this Phase 2 study is to evaluate the safety and efficacy of the KT-301 in the management of patients with CKD Stage IV. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05630729 -
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
|
N/A | |
Completed |
NCT03293446 -
AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls
|
N/A | |
Completed |
NCT04858854 -
Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2
|
N/A | |
Completed |
NCT05624840 -
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
|
||
Recruiting |
NCT05489120 -
Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)
|
N/A | |
Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
Completed |
NCT05042206 -
Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease
|
Phase 1 | |
Completed |
NCT05153174 -
Study of Sulphoraphane in Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03582982 -
Flywheel Exercise for CKD
|
N/A | |
Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
Not yet recruiting |
NCT03348839 -
Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT04330807 -
Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease
|
N/A | |
Completed |
NCT05931978 -
Effect of a CKD Dashboard on Patient Activation and Shared Decision Making
|
N/A | |
Recruiting |
NCT05543928 -
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
|
Phase 3 | |
Active, not recruiting |
NCT06037265 -
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
|
N/A | |
Completed |
NCT04617431 -
Application of Wearable Devices to Build a Self-Management Model in Chronic Kidney Disease Patients
|
N/A | |
Recruiting |
NCT04336033 -
Validation and Evaluation of a Newly Developed Mobile Diet App
|
N/A | |
Recruiting |
NCT05138419 -
A Pragmatic Approach to CKD Patient Education
|
N/A | |
Not yet recruiting |
NCT06394544 -
Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment
|
N/A | |
Recruiting |
NCT01410617 -
The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass
|
Phase 2/Phase 3 |